Prilocaine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Prilocaine: From Local Anesthesia to Papillary Conjunctivitis
One-Sentence Summary
Prilocaine is an amide-type local anesthetic, historically used for topical and infiltration anesthesia (e.g., combined with lidocaine in EMLA cream) for minor surgical, dental, and dermatologic procedures. The TxGNN model’s top-ranked prediction for this drug is Papillary Conjunctivitis, but this specific candidate is currently supported by zero clinical trials and zero publications — it is a pure knowledge-graph embedding signal with no corroborating evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Local anesthesia (topical/injectable) — not documented in the available regulatory dataset |
| Predicted New Indication | Papillary Conjunctivitis |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a data gap in the evidence pack). Based on general pharmacological knowledge, prilocaine is an amide-type local anesthetic that blocks voltage-gated sodium (Nav) channels in peripheral nerves, reducing neuronal excitability and pain signal transmission. Its established use is in local/regional anesthesia — it has no known pharmacological pathway relevant to conjunctival inflammation.
The evidence pack’s own rationale for this candidate is explicit: there is “no clinical trial or literature support, and no known mechanistic link to papillary conjunctivitis,” and the prediction is judged to be a low-confidence knowledge-graph embedding pairing rather than a biologically grounded hypothesis. No plausible connection between sodium-channel blockade and papillary conjunctivitis pathophysiology (typically allergic/mechanical, e.g., contact lens-related) is presented anywhere in the supporting data.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
Prilocaine currently holds no NDA licenses in the reviewed regulatory dataset (market status: Not Marketed; 0 total licenses on file). No product-level authorization details are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top TxGNN-ranked prediction (Papillary Conjunctivitis) has no clinical trial or literature evidence and no established mechanistic rationale — the score reflects only knowledge-graph embedding similarity, not a validated biological hypothesis. This does not meet the bar to advance past S0.
To proceed, the following is needed:
- TFDA label warnings/contraindications (currently a blocking data gap — required before any S1 safety screening)
- Confirmed mechanism of action via DrugBank API query
- Independent literature/mechanistic search specifically probing local anesthetics in ophthalmic/conjunctival inflammatory conditions
- If a mechanistic or clinical signal cannot be established, this candidate should be deprioritized in favor of other predictions in the same TxGNN batch for this drug
Note: Among the 10 TxGNN predictions generated for prilocaine, neuralgia (rank 5, score 99.34%) shows substantially stronger existing evidence — evidence level L2, decision stage S3, “Proceed with Guardrails” — supported by a completed Phase 2 trial directly testing lidocaine/prilocaine cream (NCT00916942) and a Tier-1 RCT (PMID 2493878) on lidocaine-prilocaine cream in postherpetic neuralgia. This candidate may warrant a separate, dedicated evaluation report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.